NCT04833296 is a Phase 4 clinical trial of Ropivacaine in Postoperative Pain, sponsored by Healthpoint Hospital.

Who is sponsoring NCT04833296?

NCT04833296 is sponsored by Healthpoint Hospital.

What drugs are being tested in NCT04833296?

Interventions in NCT04833296: Ropivacaine.

What condition does NCT04833296 study?

NCT04833296 studies Postoperative Pain.

Is NCT04833296 still recruiting?

NCT04833296 is currently status unknown. Last updated 6 April 2021.

Last reviewed 2021-04-06 · How we verify

NCT04833296

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

Status unknown Phase 4 Last updated 6 April 2021

What this trial tests

Phase 4 trial testing Ropivacaine in Postoperative Pain in 45 participants. Status unknown.

Timeline

1 May 2021

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Healthpoint Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	1 May 2021
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Ropivacaine (ROPIVACAINE) — full drug profile →

Conditions studied

Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Healthpoint Hospital

Who can join

18 and older, any sex, with Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to calculate the minimal effective ropivacaine concentration required achieve successful analgesic interscalene block in 90% of patients (MEAC90)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ropivacaine

Trials testing the same drug.

NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
NCT07209345 — Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy · NA · recruiting
NCT05642026 — INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures · Phase 4 · recruiting
NCT07013526 — Dexmedetomidine as Adjuvant for Suprazygomatic Maxillary Nerve Block in Children's Adenotonsillectomy · NA · not yet recruiting
NCT06925789 — Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surger · Phase 1 · withdrawn

Other Healthpoint Hospital trials

Trials by the same sponsor.

NCT04834440 — Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90) · Phase 4 · unknown
NCT03613974 — Minimum Anaesthesia Concentration of Lidocaine Required for Sciatic Popliteal Block · Phase 4 · unknown
NCT03184532 — Bedside Gastric Ultrasound for Assessment of ASA Preoperative Starving Guidelines Accuracy: Diabetic vs Non Diabetic Pat · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04833296 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Healthpoint Hospital
Last refreshed: 6 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing